Information Provided By:
Fly News Breaks for February 20, 2020
Feb 20, 2020 | 07:42 EDT
Raymond James analyst John Ransom raised his price target for Amedisys to $225 from $200 and reiterated an Outperform rating following mixed Q4 results and "noisy" 2020 guidance. In a research note to investors, Ransom says he believes that 2020 guidance includes a greater amount of conservatism than typical from an already conservative management team and that there is plenty of "wiggle room" in 1H20.
News For AMED From the Last 2 Days
There are no results for your query AMED